- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04734210
Research Study To See How Well An Eye Drop (SURF-200) Works, What Side Effects There Are, And To Compare It With Vehicle In Subjects With An Episodic Flare-Up of Dry Eye Disease
A Multicenter, Randomized, Double-Masked, Dose-Ranging Study To Compare The Ocular Safety, Tolerability, And Efficacy Of SURF-200 Ophthalmic Solution (0.02% And 0.04% Betamethasone Sodium Phosphate) To Vehicle In Subjects With A Diagnosis Of Dry Eye Disease And Experiencing An Episodic Flare Up
SURF-200 is being studied in people experiencing an episodic flare-up of their dry eye disease. SURF-200 is an investigational drug (which means the study drug is currently being tested) in the form of a sterile eye drop.
The purpose of this research study is to see how well SURF-200 works and what side effects there are, and to compare it with vehicle (placebo). The study will involve about 120 study participants at multiple research sites in the United States.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Alabama
-
Dothan, Alabama, United States, 36301
- Trinity Research Group
-
-
California
-
Azusa, California, United States, 91702
- Canyon City EyeCare
-
Mission Hills, California, United States, 91345
- North Valley Eye Medical Group, Inc.
-
Murrieta, California, United States, 92562
- LoBue Laser and Eye Medical Center
-
Newport Beach, California, United States, 92663
- Visionary Eye Institute
-
Petaluma, California, United States, 94954
- North Bay Eye Associates
-
Rancho Cordova, California, United States, 95670
- Martel Eye Medical Group
-
-
Colorado
-
Colorado Springs, Colorado, United States, 80907
- Vision Institute
-
Fort Collins, Colorado, United States, 80528
- The Eye Center of Northern Colorado
-
-
Connecticut
-
Danbury, Connecticut, United States, 06810
- Connecticut Eye Consultants, PC
-
-
Florida
-
Bradenton, Florida, United States, 34209
- The Eye Associates of Manatee
-
Clearwater, Florida, United States, 33761
- Blue Ocean Clinical Research (The Macula Center)
-
Fort Myers, Florida, United States, 33901
- Eye Associates of Fort Myers
-
Panama City, Florida, United States, 32405
- Eye Center of North Florida PA
-
-
Georgia
-
Roswell, Georgia, United States, 30076
- Coastal Research Associates, LLC
-
-
Kentucky
-
Edgewood, Kentucky, United States, 41017
- Cincinnati Eye Institute
-
Lexington, Kentucky, United States, 40517
- Kentucky Eye Institute
-
-
Minnesota
-
Bloomington, Minnesota, United States, 55420
- Chu Vision Institute
-
Hamel, Minnesota, United States, 55340
- Complete Eye Care
-
-
Missouri
-
Kansas City, Missouri, United States, 64111
- Tauber Eye Center
-
Saint Louis, Missouri, United States, 63131
- Ophthalmology Consultants Ltd.
-
-
New York
-
Poughkeepsie, New York, United States, 12603
- Alterman, Modi & Wolter
-
-
Pennsylvania
-
Cranberry Township, Pennsylvania, United States, 16066
- Scott & Christie and Associates, PC
-
Wilkes-Barre, Pennsylvania, United States, 18702
- Bucci Laser Vision
-
-
Tennessee
-
Memphis, Tennessee, United States, 38119
- Total Eye Care, PA
-
Nashville, Tennessee, United States, 37215
- West TN EyeCare dba Toyos Clinic
-
-
Texas
-
Houston, Texas, United States, 77034
- Advanced Laser Vision & Surgical Institute
-
San Antonio, Texas, United States, 78229
- R and R Eye Research, LLC
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Subjects 18 years of age and older who have a diagnosis of dry eye disease and experiencing an episodic flare up. Criteria for the diagnosis must include the following:
- UNC DEMS score of greater than or equal to 5 but less than or equal to 9
- Conjunctival hyperemia score of greater than or equal to 2 in the study eye when using the conjunctival hyperemia reference photos
- Schirmer's Tear Test score (with anesthesia) greater than 1 mm but less than or equal to12 mm in the study eye
- Subjects must be able to understand and sign the Informed Consent Form (ICF).
- Female subjects of childbearing potential must agree to and submit a negative urine pregnancy test before any study-specific procedures are performed. The subjects must be using and continue to use a suitable method of contraception for the duration of the study: spermicide with barrier, oral contraceptive, transdermal contraceptive, injectable or implantable contraceptive, intrauterine device (IUD), abstinence or surgical sterilization of a partner. If a subject is not of childbearing potential (e.g., has been postmenopausal for at least 12 months or is premenarchal, or has undergone a hysterectomy, bilateral oophorectomy or a bilateral tubal ligation), a urine pregnancy test and use of a suitable method of contraception for the duration of the study will not be required.
- Subjects must have a best-corrected visual acuity (BCVA) of at least +1.0 log of the minimum angle of resolution (logMAR) (Snellen equivalent of 20/200) in the non-study eye (fellow eye).
- Subjects must have an intraocular pressure (IOP) of >8 mmHg and ≤22 mmHg in the study eye.
- Subjects who are on Restasis, Xiidra or other cyclosporine ophthalmic eye drops must be on a stable dose for at least 4 months prior to Screening Visit 1 (Day -14 to Day 0) and remain compliant with the use of these medications throughout the duration of this study.
- Subjects who are on artificial tears, oral antihistamines, beta blockers and diuretics must be on a stable dose for at least 1 month prior to Screening Visit 1 (Day -14 to Day 0) and remain compliant with the use of these medications throughout the duration of this study.
- Subjects must be willing and able to attend all study visits and follow all instructions.
- Subjects must be able to self-instill the study drug (if unable, a caregiver must be available to instill all doses of the study drug).
- Have a history of use or desire to use an eye drop for dry eye symptoms for longer than the past 6 months.
Exclusion Criteria:
- Females who are pregnant or nursing or planning to become pregnant during the study. Females of childbearing potential (not surgically sterilized or postmenopausal) may not participate in the study if they do not agree to use adequate birth control methods for the duration of the study.
- Use of contact lenses in either eye during the study. Contact lens wear must have been discontinued at least 2 weeks prior to Baseline/Randomization Visit 2 (Day 1).
- Use of corticosteroids or nonsteroidal anti-inflammatory agents (NSAID) (except oral doses of aspirin at 81 mg/day or lower) within 2 weeks of the initiation of study drug at Baseline/Randomization Visit 2 (Day 1) and for the remainder of the study.
- Inhaled, ingested, sublingual, transdermal or topical products containing marijuana, tetrahydrocannabinol (THC) or cannabidiol (CBD) within 7 days of the first dose of study drug at Baseline/Randomization Visit 2 (Day 1) and for the remainder of the study.
- Presence or history of treatment with systemic immunosuppressive or chemotherapeutic agents.
- History of high IOP response to steroids.
- Participated in an ophthalmic investigational product clinical trial within 30 days of Screening Visit 1 (Day -14 to Day 0).
- Active collagen vascular disorder or autoimmune disease.
- A condition or a situation, which in the investigator's opinion may put the subject at increased risk, confound study data, or interfere significantly with the subject's study participation.
- Known hypersensitivity to any component of the study drug or procedural medications.
- Known hypersensitivity to steroids.
- Any active corneal epithelial/stromal pathology noted in the study eye at Screening Visit 1 (Day -14 to Day 0).
- Any history of corneal surgery in the study eye (including corneal crosslinking, radial keratotomy, corneal transplant, or LASIK).
- Any ocular surgery in the study eye within the past year.
- Subject has punctal occlusion with any modality or a change in punctal plug status in either eye within the 3 months prior to Screening Visit 1 (Day -14 to Day 0).
- Subject has a history of glaucoma.
- Subject has a history of herpes simplex infection in either eye.
- Subject has active corneal, conjunctival or canalicular pathology (including ocular infection [bacterial, viral or fungal]) in either eye. Specifically, active viral diseases of the cornea and conjunctiva including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella, and mycobacterial infection of either eye and fungal diseases of the ocular structures (such as fungal keratitis).
- Subject has thinning of the cornea or sclera in the study eye.
- Subject has active anterior blepharitis in the study eye.
- Subject has a history of uveitis in the study eye.
- Subject is suffering from alcohol and/or drug abuse.
- Subject has tested positive for the COVID-19 virus within 30 days prior to Screening Visit 1 (Day -14 to Day 0).
- Subject has previously received treatment in this study protocol.
- Subject is taking a medication, that in the opinion of the investigator, might interfere with the study parameters.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: SURF-200 (0.02% betamethasone sodium phosphate in vehicle)
One drop twice daily (BID) in the study eye for 14 days.
|
topical corticosteroid solution
|
Experimental: SURF-200 (0.04% betamethasone sodium phosphate in vehicle)
One drop BID in the study eye for 14 days.
|
topical corticosteroid solution
|
Placebo Comparator: Vehicle
One drop BID in the study eye for 14 days.
|
topical vehicle solution
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
UNC DEMS Score
Time Frame: Day 8
|
A minimum reduction of 1 unit or more in patient-reported dry eye disease symptoms and reduction of impact of symptoms with SURF-200 as compared to vehicle (as measured by the University of North Carolina [UNC] Dry Eye Management Scale [DEMS]).
|
Day 8
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
UNC DEMS Score
Time Frame: Day 15
|
A minimum reduction of 1 unit or more in patient-reported dry eye disease symptoms and reduction of impact of symptoms with SURF-200 as compared to vehicle (as measured by the University of North Carolina [UNC] Dry Eye Management Scale [DEMS]).
|
Day 15
|
Conjunctival Hyperemia Assessment
Time Frame: Day 8
|
A minimum reduction of 0.5 points or more in conjunctival hyperemia with SURF-200 as compared to vehicle using the Conjunctival Hyperemia Assessment 4 point scale (0-3) in the study eye.
|
Day 8
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Kamran Hosseini, MD, PhD, Surface Ophthalmics, Inc. (formerly Surface Pharmaceuticals, Inc.)
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Lacrimal Apparatus Diseases
- Keratoconjunctivitis
- Conjunctivitis
- Conjunctival Diseases
- Keratitis
- Corneal Diseases
- Eye Diseases
- Dry Eye Syndromes
- Keratoconjunctivitis Sicca
- Physiological Effects of Drugs
- Anti-Inflammatory Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Anti-Asthmatic Agents
- Respiratory System Agents
- Betamethasone
- Betamethasone Valerate
- Betamethasone-17,21-dipropionate
- Betamethasone benzoate
- Betamethasone sodium phosphate
Other Study ID Numbers
- C-200-001
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Dry Eye Disease
-
Bausch & Lomb IncorporatedCompletedDry Eye Disease (DED)United States
-
Gordon Schanzlin New VisionRecruitingDry Eye | Dry Eye Disease | Evaporative Dry Eye | Kerato Conjunctivitis Sicca | Evaporative Dry Eye Disease | Dry Eye, EvaporativeUnited States
-
AllerganCompletedDry Eye Syndrome | Dry Eye DiseaseUnited States
-
Senju Pharmaceutical Co., Ltd.CompletedDry Eye Syndrome | Dry Eye DiseaseUnited States
-
LantibioRiver Plate Biotechnology, Inc.; Rx Development Resources, LLCCompletedSafety and Efficacy Assessment of Vismed® (Sodium Hyaluronate) for the Treatment of Dry Eye SyndromeDry Eye DiseaseUnited States
-
Fundación Oftalmológica Los AndesAlcon ResearchNot yet recruitingCataract | Dry Eye Syndrome | Dry Eye Disease | Phacoemulsification | Evaporative Dry Eye
-
Vienna Institute for Research in Ocular SurgeryTerminated
-
Novaliq GmbHCompletedDry Eye Disease (DED)United States
-
Novaliq GmbHCompletedDry Eye Disease (DED)United States
-
Oyster Point Pharma, Inc.CompletedDry Eye Disease (DED)United States
Clinical Trials on 0.02% Betamethasone Sodium Phosphate
-
HaEmek Medical Center, IsraelWithdrawnComparison of 2 Doses of Corticosteroid Subacromial Injections for the Treatment of Painful ShoulderBursitis | TendonitisIsrael
-
University of Southern CaliforniaNot yet recruitingPrematurity | Neonatal HypoglycemiaUnited States
-
Cairo UniversityUnknownChronic Non Bacterial Prostatitis
-
Seoul National University HospitalRecruitingTwin Pregnancy, Antepartum Condition or ComplicationKorea, Republic of
-
Umeå UniversityRecruitingPain | Bleeding | PONV | TonsillectomySweden
-
Thammasat UniversityActive, not recruitingKnee OsteoarthritisThailand
-
Edward KasaraskisCompletedFamilial Amyotrophic Lateral SclerosisUnited States
-
Assistance Publique - Hôpitaux de ParisCompleted
-
Sultan Abdulhamid Han Training and Research Hospital...RecruitingSubacromial Impingement Syndrome | Central SensitisationTurkey